Innovative Approaches for Maximizing Bioavailability, Accelerating Product Time-To-Market and Lifecycle Management of Both Small and Large Molecule DrugsREGISTER NOW
Most drugs on today’s market display poor solubility, but the use of modern solubilization technologies can improve a drug product's bioavailability and performance. Even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it is bioavailable.
Most of the drugs and APIs currently on the market are poorly water-soluble and need to have their bioavailability improved through the development of enabled formulations and patient-centric delivery mechanisms. Finding the solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms.
Additionally, biopharmaceutical firms hoping to develop oral delivery alternatives for injectable biologics will also need to work out how to ensure that their products are bioavailable, safe and effective. Small-and large-molecule therapeutics urgently need to overcome drug formulation and delivery challenges in order to improve bioavailability and therapeutic performance.
Curtis & Coulter’s Global Drug Bioavailability Enhancement Summit will examine and showcase the industry’s latest formulation and delivery technologies for enhancing solubility and maximizing bioavailability. Learn directly from leading global formulation experts in both industry and academia on how to effectively develop poorly soluble drugs into scientifically unique, compliant, patient-centric formulations. Additionally, learn innovative strategies to significantly reduce product development timelines, brush up on the latest regulatory requirements and learn multiple innovative strategies to optimize and enhance your product portfolio.
Conference Only: $2,295
Additional group packs available when enquiring via firstname.lastname@example.org
- Hear from 35+ speakers on two separate tracks discussing the latest bioavailability enhancement take-home strategies and examples - Engage in multiple networking sessions and breaks over two full days to hear from formulation development and bioavailability enhancement solution providers - 120+ senior participants spanning pharma, biotech and specialty technology companies - 2016’s program includes an emphasis on how to select the ideal excipients for both small molecules and biologics - Dynamic exhibit hall with multiple leading formulation and bioavailability enhancement providers
- Rationale formulation design for poorly soluble compounds - Improving oral bioavailability for poorly water-soluble drug candidates - Solubilization approaches for parenteral routes of administration - Enhancing API bioavailability via nanotechnology for drug delivery - Improving oral modified release dosage forms - Controlled release / modified release drug delivery - API crystal forms and their bioavailability - Patent-centric formulation approaches - Lipid-based formulations - Optimizing biologics development - Animal models - In-vivo – in-vitro correlation - Dosage strategy
Pharmaceutical, biotech and medical device professionals responsible for: - Formulation/Preformulation - Solubility/Solubilization - Pharmaceutics/Biopharmaceutics - Pharmacokinetics/Pharmacodynamics/DMPK - Manufacturing - CMC - Drug Delivery - Medicinal Chemistry - Preclinical Development - Analytical Development - Material Science - Toxicology - Physicochemistry - Process R&D This Program Will Also Be of Interest to: - Solubility and Formulation Service Providers - Drug Delivery Service Providers - API Manufacturers - CROs - CMOs
Questions/Comments: Contact Paul Himberger at +1 (646) 604 2830 or email@example.com